Pharmacist-Embedded Liver Fibrosis Screening Finds Hidden Cirrhosis in Diabetes
This feasibility pilot demonstrates that ambulatory pharmacists comanaging type 2 diabetes can operationalize guideline-recommended MASLD fibrosis risk stratification under existing collaborative care agreements, closing a documented primary care screening gap.
📅 Journal publication: Oct 2026·Last updated: Oct 7, 2026
MASLDtype 2 diabetesliver fibrosisFIB-4vibration-controlled transient elastographyVCTEFibroScanambulatory care pharmacistcollaborative care agreementfeasibility studysafety netresmetiromGLP-1 receptor agonistmanaged care pharmacyClinical Pharmacy Practice
Pharmacists enhance liver disease detection in diabetes care.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is common in type 2 diabetes mellitus (T2DM) but often undiagnosed. Integrating risk stratification in pharmacy care could enhance detection. Post-intervention, 87% of patients with elevated Fibrosis-4 index (FIB-4) scores were referred for vibration-controlled transient elastography (VCTE), with 85% completing it. This led to the identification of eight new cases of fibrosis. The study shows that pharmacists can effectively integrate MASLD risk assessment into diabetic care workflows, improving referral rates and fibrosis detection. However, this was a feasibility pilot study and further research is needed to assess scalability. Pharmacist integration in diabetes management improves liver fibrosis detection in primary care.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.